Cannabis is the most widely used illicit drug in the United States and Europe. In recent years, a range of new substances with cannabis-like effects—known as synthetic cannabinoids (SCs)—have suddenly burst on the drug scene. However, there is limited information about the clinical hazards linked to the use of these emerging substances. This review summarizes the literature to date relating the health effects of SCs. Method: A systematic literature review of original case studies was performed using PubMed and Web of Science (January 1980–July 2015). Only articles in which a drug screening was reported were included in this review.
Results
Forty-six articles meeting the inclusion criteria were included in this review, reporting data on 114 patients who went to hospital emergency departments after exposure to SCs. The majority of patients were adolescent or young adult males (14–25 years; 24.5 ± 10.1 years). The most common route of administration was smoking. The SCs most involved were John William Huffman (JWH) derivatives, followed by XRL-11, ADB-PINACA, AM-2201, MAM-2201, and 5F-PB-22. This analysis showed that the use of these substances may cause minor and moderate side effects similar to those of cannabis intoxication, including tachycardia, nausea, somnolence, hallucinations, paranoia, xerostomia, and injected conjunctivae among others. However, atypical cannabis intoxication effects and worse complications (such as renal injuries, aggressiveness, cerebral ischemia, myocardial infarction, etc.) were also observed, which led to a significant morbidity were also observed. Some SCs were highlighted as being involved in 24 cases of deaths.
Conclusions
In this review, the nature and frequency of the signs and symptoms of SC poisoning were estimated in order to inform health professionals about the health risks of these new and emerging substances.
European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe. An update from the EU Early Warning System. Official Publication of the European Union. Luxembourg; 2015;1–12.
2.
GundersonEW, HaugheyHM, Ait-DaoudN, JoshiAS, HartCL. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict.2012;21:320–326.
3.
UchiyamaN, KawamuraM, Kikura-HanajiriR, GodaY. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int.2013;227:21–32.
4.
RodgmanC, KinzieE, LeimbachE. Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. Am J Emerg Med.2011;29:232. doi: 10.1016/j.ajem.2010.07.020
5.
Psychonaut Web Mapping Research Group. Spice Report. London, UK: Institute of Psychiatry, King's College London; 2009. http://vanilla47.com/PDFs/MDPV/Spice%20Report.pdf. Accessed February 19, 2016.
6.
GundersonEW, HaugheyHM, Ait-DaoudN, JoshiAS, HartCL. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus.2014;35:184–189.
7.
Every-PalmerS. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend.2011;117:152–157.
8.
VandreyR, DunnKE, FryJA, GirlingER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend.2012;120:238–241.
9.
SoussanC, KjellgrenA. The flip side of ‘Spice’: the adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. Nord Stud Alcohol Drug.2014;31:207–220.
10.
ZimmermannUS, WinkelmannPR, SchulzK. Withdrawal phenomena and dependence syndrome after the consumption of “Spice Gold”. Dtsch Ärztebl Int.2009;106:464–467.
11.
MüllerH, SperlingW, KöhrmannM, HuttnerHB, KornhuberJ, MalerJM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res.2010;118:309–310.
12.
McQuadeD, HudsonS, DarganPI. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol.2013;69:373–376.
13.
TofighiB, LeeJD. Internet highs-seizures after consumption of synthetic cannabinoids. J Addict Med.2012;6:240–241.
14.
LapointJ, JamesLP, MoranCL, NelsonLS, HoffmanRS, MoranJH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol.2011;49:760–764.
15.
SeifertSA, BrazwellEM. Seizure and acute kidney injury associated with synthetic cannabinoid use. In: Annu Meet NACCT; [September 27 – October 2]; [Hyatt Regency, Atlanta, USA]. 51:204; 2013;667. doi: 10.3109/15563650.2013.817658
16.
HopkinsCY, GilchristBL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med.2013;45:544–546.
17.
PantS, DeshmukhA, DholariaB, . Spicy seizure. Am J Med Sci.2012;344:67–68.
18.
SethiR, ThapaN, SaxenaA, ChahilR. “K2/Spice”: have you updated your differentials? A case report. Prim Care Companion CNS Disord.2013;15. doi: 10.4088/PCC.12l01402.
19.
BenfordDM, CaplanJP. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics. 2011;52:295. doi: 10.1016/j.psym.2011.01.004
20.
QuanD, HaaseD, LevitanR. Legal drugs of abuse. Emerg Med Rep.2011;32:237–247.
21.
PeglowS, BuchnerJ, BriscoeG. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict.2012;21:287–288.
22.
IbrahimS, Al-SaffarF, WannenburgT. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol.2014;2014:120607. doi: 10.1155/2014/120607
23.
UkaigweA, KarmacharyaP, DonatoA. A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med’. 2014;2014:167098. doi: 10.1155/2014/167098
24.
MckeeverRG, VearrierD, JacobsD, LaSalaG, OkanekuJ, GreenbergMI. K2-not the spice of life, synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol.2015;11:129–131.
25.
TakematsuM, HoffmanRS, NelsonLS, SchechterJM, MoranJH, WienerSW. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol.2014;52:973–975.
26.
SchepLJ, SlaughterRJ, HudsonS, PlaceR, WattsM. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol.2015;34:557–560.
27.
DerungsA, SchwaningerAE, MansellaG, BingisserR, KraemerT, LiechtiME. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol.2013;31:164–171.
28.
ThorntonSL, WoodC, FriesenMW, GeronaRR. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol.2013;51:189–190.
29.
SaitoT, NameraA, MiuraN, . A fatal case of MAM-2201 poisoning. Forensic Toxicol.2013;31:333–337.
30.
SasakiC, SaitoT, ShinozukaT, . A case of death caused by abuse of a synthetic cannabinoid N-1-naphtalenyl-1-pentyl-1H-indole-3-carboxamide. Forensic Toxicol.2015;33:165–169.
31.
HasegawaK, WuritaA, MinakataK, . Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products. Forensic Toxicol.2015;33:112–121.
32.
PattonAL, ChimalakondaKC, MoranCL, . K2 toxicity: fatal case of psychiatric complications following AM-2201 exposure. J Forensic Sci.2013;58:1676–1680.
33.
Hermanns-ClausenM, KneiselS, SzaboB, AuwärterV. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2012;108:534–544.
34.
MusshoffF, MadeaB, Kernbach-WightonG, . Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med.2014;128:59–64.
35.
SimmonsJ, CookmanL, KangC, SkinnerC. Three cases of “Spice” exposure. Clin Toxicol.2011;49:431–433.
36.
HarrisCR, BrownA. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med.2013;44:360–366.
37.
SimmonsJ, SkinnerCG, WilliamsJ, KangCS, SchwartzMD, WillsBK. Intoxication from smoking “Spice”. Ann Emerg Med.2011;57:187–188.
38.
MirA, ObafemiA, YoungA, KaneC. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128:e1622–1627.
Van der VeerN, FridayJ. Persistent psychosis following the use of Spice. Schizophr Res.2011;130:285–286.
41.
Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use—multiple states, 2012. MMWR Morb Mortal Wkly Rep.2013;62:93–98.
42.
SchwartzMD, TreckiJ, EdisonLA, . A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med.2015;48:573–580.
43.
HurstD, LoefflerG, McLayR. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168:1119. doi: 10.1176/appi.ajp.2011.11010176.
44.
BhanushaliGK, JainG, FatimaH, LeischLJ, Thornley-BrownD. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol.2013;8:523–526.
45.
HeathTS, BurroughsZ, ThompsonAJ, TecklenburgFW. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther.2012;17:177–181.
46.
CohenJ, MorrisonS, GreenbergJ, SaidinejadM. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics. 2012;129:1064–1067.
47.
BehonickG, ShanksKG, FirchauDJ, . Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol.2014;38:559–562.
48.
ShanksKG, DahnT, TerrellAR. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol.2012;36:145–152.
49.
KronstrandR, RomanM, AnderssonM, EklundA. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol.2013;37:534–541.
50.
NaviglioS, PapantiD, MoressaV, VenturaA. An adolescent with an altered state of mind. BMJ. 2015;350. doi: 10.1136/bmj.h299
51.
SchneirAB, BaumbacherT. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol.2012;8:62–64.
DemirciH, CosarR, CiftciO, SariIK. Atypical diabetic ketoacidosis: case report. Balk Med J.2015;32:124–126.
54.
YoungA, SchwarzE, MedinaG, . Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med.2012;30:1320.e5–1320.e7.
55.
LapointJ, NelsonLS. Synthetic cannabinoids: the newest, almost illicit drug of abuse. Emerg Med.2011;26–28.
Substances Abuse and Mental Health Services Administration (SAMHSA). Drug Abuse Warning Network. 2011: National Estimates of Drug-Related Emergency Department Visits. http://www.samhsa.gov/data/DAWN.aspx. Published2013. Accessed June 8, 2015.
RomingerA, CummingP, XiongG, . Effects of acute detoxification of the herbal blend “Spice Gold” on dopamine D2/3 receptor availability: a [18F]fallypride PET study. Eur Neuropsychopharmacol.2013;23:1606–1610.
AuwärterV, DresenS, WeinmannW, MüllerM, PützM, FerreirosN. “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs?J Mass Spectrom.2009;44:832–837.
68.
BesliGE, IkizMA, YildirimS, SaltikS. Synthetic cannabinoid abuse in adolescents: a case series. J Emerg Med.2015;49:644–650.
69.
HallW, DegenhardtL. Adverse health effects of non-medical cannabis use. Lancet.2009;374:1383–1391.
KarilaL, RouxP, RollandB, . Acute and long-term effects of cannabis use: a review. Curr Pharm Des.2014;20:4112–4118.
72.
WinstockA, BarrattMJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural Cannabis in a large global sample. Drug Alcohol Depend.2013;131:106–111.
73.
ComptonDR, JohnsonMR, MelvinLS, MartinBR. Pharmacological profile of a series of bicyclic cannnabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther.1992;260:201–209.
74.
PsychoyosD, VinodKY. Marijuana, Spice ‘herbal high’, and early neural development: implications for rescheduling and legalization. Drug Test Anal.2013;5:27–45.
75.
JerryJ, CollinsG, StreenD. Synthetic legal intoxicating drugs: the emerging “incense” and “bath salt” phenomenon. Cleve Clin J Med.2012;79:258–264.
76.
BrentsLK, ReichardEE, ZimmermanSM, MoranJH, FantegrossiWE, PratherPL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE. 2011;6:e21917. doi: 10.1371/journal.pone.0021917
77.
SeelyKA, LapointJ, MoranJH, FattoreL. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:234–243.
78.
PertweeRG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabinol and tetrahydrocannabivarin. Br J Pharmacol.2008;153:199–215.
79.
AlexandreJ, DebruyneD, CoquerelA, Le BoisselierR. Comment on ‘A unique case of cardiac arrest following K2 abuse’. Case Rep Cardiol.2015;2015:739149. doi: 10.1155/2015/739149
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
